Denali Therapeutics Inc.
Denali Therapeutics is a clinical-stage biopharmaceutical company developing barrier-crossing therapeutics for neurodegenerative and lysosomal storage diseases. Its core platform is designed to improve delivery of biologics across the blood-brain barrier, with lead programs including tividenofusp alfa for Hunter syndrome and DNL126 for Sanfilippo syndrome type A.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaClinical and pre-commercial biologic drug candidates for lysosomal storage diseases such as Hunter syndrome and Sanfilippo syndrome.
Programs targeting diseases including Alzheimer’s, Parkinson’s, and FTD using the company’s transport vehicle platform.
Barrier-crossing delivery technology intended to transport biotherapeutics into the brain and throughout the body.
Revenue from partnering arrangements, milestones, option fees, and other collaboration-related payments.
Asiakkaat
Denali does not yet sell approved products, so its current economic counterparties are collaboration partners rather than end-market patients. Revenue to date has come from Takeda, Sanofi, and Biogen through collaboration and license agreements, while future commercial customers would be patients, caregivers, and healthcare systems if its programs are approved.
Takeda, Sanofi, and Biogen pay for partnered research, development, and potential milestone/royalty economics.
Families affected by Hunter syndrome and Sanfilippo syndrome are the intended end users for lead programs.
Specialist physicians would diagnose, prescribe, and monitor treatment if Denali’s therapies are approved.
Insurers and treatment centers would reimburse and administer approved therapies in commercial markets.
Strategia
Denali’s strategy is to use its TV platform to discover and develop barrier-crossing biologics, then convert that platform into commercial products in rare lysosomal storage diseases. Management’s D3X3 plan emphasizes two growing commercial brands, multiple clinical proof-of-concept readouts, and several new programs entering the clinic to broaden the pipeline and validate the platform.
A first approved product would convert Denali from a pure R&D company into a commercial rare-disease franchise.
A second launch would reduce dependence on a single asset and strengthen the rare-disease platform.
Clinical proof-of-concept in several programs would support broader partnering and pipeline expansion.
In-house clinical manufacturing can improve speed, flexibility, and supply reliability as programs advance.
Maantiede
Denali is headquartered in South San Francisco, California, with additional operations in Salt Lake City, Utah and Zurich, Switzerland. The company’s business is currently concentrated in the United States, but its collaboration model and future commercialization plans create exposure to Europe and other international markets.
Riskit
Denali remains a clinical-stage company with no approved products, so its value depends heavily on regulatory success, trial execution, and access to capital. The business also faces concentration risk in a small number of lead assets and collaboration counterparties, while future commercialization adds manufacturing, reimbursement, and launch-execution risk.
- Clinical-stage development riskVaikutus: KriittinenTodennäköisyys: Korkea
The company has not completed a pivotal trial or obtained marketing approval, so outcomes remain uncertain.
Kohdistuu: All pipeline programs
- Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Korkea
Lead programs depend on FDA and potentially EMA review, including accelerated approval pathways.
Kohdistuu - Capital and dilution riskVaikutus: KorkeaTodennäköisyys: Korkea
Persistent operating losses and negative cash flow require ongoing external funding.
Kohdistuu: Company-wide
- Manufacturing and supply chain riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Denali relies on CDMOs for most supply and is still building internal capabilities.
Kohdistuu: Clinical and future commercial supply
- Partner concentration riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Current revenue is tied to a small number of collaboration partners and agreements.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätRevenue from Takeda, Sanofi, and Biogen requires judgment on allocation and timing of performance obligations.
Vaikutus: Can cause quarter-to-quarter volatility in reported revenue.
Clinical and manufacturing expenses are accrued based on estimates for services received but not yet invoiced.
Vaikutus: Affects operating expenses and liabilities.
Equity awards are a meaningful part of employee compensation at a clinical-stage biotech.
Vaikutus: Increases non-cash operating expense and affects loss metrics.
Facilities in South San Francisco, Salt Lake City, and Zurich create right-of-use assets and lease liabilities.
Vaikutus: Affects balance sheet leverage and operating expense presentation.
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Filana Therapeutics, Inc
FLNA · Pharmaceutical Preparations
Cognition Therapeutics, Inc
CGTX · Biological Products, (No Diagnostic Substances)
Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on small-molecule therapies for age-related degenerative diseases of the central nervous system and retina.
Monopar Therapeutics
MNPR · Pharmaceutical Preparations
Monopar Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing drug candidates for Wilson disease and advanced cancers.
Taysha Gene Therapies, Inc.
TSHA · Biological Products, (No Diagnostic Substances)
Zenas BioPharma, Inc.
ZBIO · Pharmaceutical Preparations
Zenas BioPharma is a U.S.-based clinical-stage biopharmaceutical company focused on immunology and inflammation therapies for autoimmune diseases.
Larimar Therapeutics, Inc.
LRMR · Pharmaceutical Preparations
Päivitetty: 24.9.2026